Creo Medical Group PLC Director/PDMR Shareholding (4135B)
10 January 2018 - 4:43AM
UK Regulatory
TIDMCREO
RNS Number : 4135B
Creo Medical Group PLC
09 January 2018
Creo Medical Group plc
Director/PDMR Dealing
The Company announces that on 9 January 2018, Steven Morris,
Chief Operating Officer and a PDMR, transferred 115,000 ordinary
shares from his personal holding to his self-invested personal
pension (SIPP) at a price of 68.0p per share. Furthermore, his SIPP
purchased an additional 325 ordinary shares in the Company at a
price of 68.0p per share. Following these transactions, Mr Morris's
total interest in ordinary shares is 115,325 ordinary shares.
Template for notification and public disclosure of transactions
by persons discharging managerial responsibilities and persons
closely associated with them
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ------------------------------------------------------------
a) Name Steven Morris
--- ------------------------- ---------------------------------
2 Reason for the notification
--- ------------------------------------------------------------
a) Position/status Chief Operating Officer
--- ------------------------- ---------------------------------
b) Initial notification Initial
/Amendment
--- ------------------------- ---------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ------------------------------------------------------------
a) Name Creo Medical Group plc
--- ------------------------- ---------------------------------
b) LEI 213800H188ZDCWWXFA21
--- ------------------------- ---------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ------------------------------------------------------------
a) Description of
the financial Ordinary shares of GBP0.001
instrument, type each
of instrument
Identification GB00BZ1BLL44
code
--- ------------------------- ---------------------------------
b) Nature of the Transfer of ordinary shares
transaction to SIPP via sale and purchase
--- ------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
------------------ ----------
Sale of shares
from personal
holding at
68.0p per share 115,000
------------------ ----------
Purchase by
SIPP at 68.0p
per share 115,325
------------------ ----------
--- ------------------------- ---------------------------------
d) Aggregated information
- Aggregated volume
- Price
Weighted average price of
68.0 pence per share
--- ------------------------- ---------------------------------
e) Date of the transaction 9 January 2018
--- ------------------------- ---------------------------------
f) Place of the transaction London Stock Exchange
--- ------------------------- ---------------------------------
Contacts
Creo Medical: Cenkos: FTI Consulting:
Richard Rees Camilla Hume/Mark Brett Pollard
+44 (0)129 160 6005 Connelly (NOMAD) / Mo Noonan
Richard.Rees@creomedical.com Michael Johnson +44 (0)203 727
/ Russell Kerr 1000
(Sales) creo@fticonsulting.com
+44 (0)207 397
8900
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and radiowave energy to surgical endoscopy. Creo
has developed CROMA, an electrosurgical platform that combines
bipolar radiofrequency for precise localised cutting and microwave
for controlled coagulation. This technology provides physicians
with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring its CROMA platform to market
through a suite of medical devices which the Company has designed,
initially for the emerging field of GI therapeutic endoscopy, an
area with high unmet needs. The CROMA platform will be developed
further for bronchoscopy and laparoscopy procedures. The Company
believes its technology can impact the landscape of surgery and
endoscopy by providing safer, less-invasive and more cost-efficient
option of treatment.
For more information about Creo Medical please see our website,
www.creomedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLLFFDLSIAIIT
(END) Dow Jones Newswires
January 09, 2018 12:43 ET (17:43 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024